Food and Drug Administration; Delegation of Authorities, 22497 [2014-09033]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 77 / Tuesday, April 22, 2014 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
before May 22, 2014. Write ‘‘FTC
Generic Clearance ICR, Project No.
P035201’’ on your comment. Your
comment—including your name and
your state—will be placed on the public
record of this proceeding, including, to
the extent practicable, on the public
Commission Web site, at https://
www.ftc.gov/os/publiccomments.shtm.
As a matter of discretion, the
Commission tries to remove individuals’
home contact information from
comments before placing them on the
Commission Web site.
Because your comment will be made
public, you are solely responsible for
making sure that your comment doesn’t
include any sensitive personal
information, like anyone’s Social
Security number, date of birth, driver’s
license number or other state
identification number or foreign country
equivalent, passport number, financial
account number, or credit or debit card
number. You are also solely responsible
for making sure that your comment
doesn’t include any sensitive health
information, like medical records or
other individually identifiable health
information. In addition, don’t include
any ‘‘[t]rade secret or any commercial or
financial information which is obtained
from any person and which is privileged
or confidential . . ., ’’ as provided in
Section 6(f) of the FTC Act, 15 U.S.C.
46(f), and FTC Rule 4.10(a)(2), 16 CFR
4.10(a)(2). If you want the Commission
to give your comment confidential
treatment, you must file it in paper
form, with a request for confidential
treatment, and you have to follow the
procedure explained in FTC Rule 4.9(c),
16 CFR 4.9(c).2 Your comment will be
kept confidential only if the FTC
General Counsel grants your request in
accordance with the law and the public
interest.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online, or to send them to the
Commission by courier or overnight
service. To make sure that the
Commission considers your online
comment, you must file it at https://
2 In particular, the written request for confidential
treatment that accompanies the comment must
include the factual and legal basis for the request,
and must identify the specific portions of the
comment to be withheld from the public record. See
FTC Rule 4.9(c), 16 CFR 4.9(c).
VerDate Mar<15>2010
19:37 Apr 21, 2014
Jkt 232001
ftcpublic.commentworks.com/ftc/
genericclearancepra2 by following the
instructions on the web-based form. If
this Notice appears at https://
www.regulations.gov/#!home, you also
may file a comment through that Web
site.
If you file your comment on paper,
write ‘‘FTC Generic Clearance ICR,
Project No. P035201’’ on your comment
and on the envelope, and mail or deliver
it to the following address: Federal
Trade Commission, Office of the
Secretary, Room H–113 (Annex J), 600
Pennsylvania Avenue NW., Washington,
DC 20580. If possible, submit your
paper comment to the Commission by
courier or overnight service.
Comments on any proposed
information collection requirements
subject to review under the PRA should
additionally be submitted to OMB. If
sent by U.S. mail, they should be
addressed to Office of Information and
Regulatory Affairs, Office of
Management and Budget, Attention:
Desk Officer for the Federal Trade
Commission, New Executive Office
Building, Docket Library, Room 10102,
725 17th Street NW., Washington, DC
20503. Comments sent to OMB by U.S.
postal mail, however, are subject to
delays due to heightened security
precautions. Thus, comments instead
should be sent by facsimile to (202)
395–5167.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before May 22, 2014. You can find more
information, including routine uses
permitted by the Privacy Act, in the
Commission’s privacy policy, at https://
www.ftc.gov/ftc/privacy.htm.
David C. Shonka,
Principal Deputy General Counsel.
[FR Doc. 2014–09173 Filed 4–21–14; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration;
Delegation of Authorities
Notice is hereby given that I have
delegated to the Commissioner, Food
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
22497
and Drug Administration (FDA), with
authority to re-delegate, the authorities
vested in the Secretary of the
Department of Health and Human
Services under the Drug Quality and
Security Act (DQSA), Public Law 113–
54, insofar as these authorities pertain to
the functions and operations of FDA.
This delegation includes, but is not
limited to, authority to communicate
with state Boards of Pharmacy under
Section 105 of the DQSA.
This delegation shall be exercised in
accordance with the Department’s
applicable policies, procedures, and
guidelines.
I hereby affirm and ratify any actions
taken by the Commissioner, FDA, or
other FDA officials that involved the
exercise of these authorities prior to the
effective date of this delegation.
This delegation of authorities is
effective upon date of signature.
Authority: 44 U.S.C. 3101.
Dated: April 11, 2014.
Kathleen Sebelius,
Secretary.
[FR Doc. 2014–09033 Filed 4–21–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
AGENCY:
ACTION:
Notice.
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project:
‘‘SelectMD 2.0 Clinician Choice
Experiment.’’ In accordance with the
Paperwork Reduction Act of 1995, 44
U.S.C. 3506(c)(2)(A), AHRQ invites the
public to comment on this proposed
information collection.
SUMMARY:
This proposed information collection
was previously published in the Federal
E:\FR\FM\22APN1.SGM
22APN1
]]>Agencies
[Federal Register Volume 79, Number 77 (Tuesday, April 22, 2014)]
[Notices]
[Page 22497]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09033]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration; Delegation of Authorities
Notice is hereby given that I have delegated to the Commissioner,
Food and Drug Administration (FDA), with authority to re-delegate, the
authorities vested in the Secretary of the Department of Health and
Human Services under the Drug Quality and Security Act (DQSA), Public
Law 113-54, insofar as these authorities pertain to the functions and
operations of FDA. This delegation includes, but is not limited to,
authority to communicate with state Boards of Pharmacy under Section
105 of the DQSA.
This delegation shall be exercised in accordance with the
Department's applicable policies, procedures, and guidelines.
I hereby affirm and ratify any actions taken by the Commissioner,
FDA, or other FDA officials that involved the exercise of these
authorities prior to the effective date of this delegation.
This delegation of authorities is effective upon date of signature.
Authority: 44 U.S.C. 3101.
Dated: April 11, 2014.
Kathleen Sebelius,
Secretary.
[FR Doc. 2014-09033 Filed 4-21-14; 8:45 am]
BILLING CODE 4160-01-P
